Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02724540 · ClinicalTrials.gov registry record · Phase 2
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver
A Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT02724540 is a Phase 2 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 162 participants.
The verdict
NCT02724540, a Phase 2 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembolization will be nearly twice as durable as bland embolization; thatis, the hazard ratio for HPFS will be 1.76 or better.
Interventions
- COMBINATION_PRODUCT Transarterial chemoembolization
- DEVICE Bland Embolization
- COMBINATION_PRODUCT Drug Eluting Beads Embolization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2016-03 |
| Est. Completion | 2024-11-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02724540
The ClinicalTrials.gov registry entry for NCT02724540 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Transarterial chemoembolization is the first listed.
NCT02724540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02724540 about?
NCT02724540 is a clinical study titled "Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver". The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembo...
What is the current status of trial NCT02724540?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2016-03. Estimated completion is 2024-11-08.
What interventions are being tested in trial NCT02724540?
The interventions under investigation include: Transarterial chemoembolization (COMBINATION_PRODUCT), Bland Embolization (DEVICE), Drug Eluting Beads Embolization (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT02724540?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.